Efalizumab (anti-CD11a), a targeted, reversible T-cell modulator, is a humanized monoclonal antibody that provides a rapid onset of action of clinical benefit and has been studied up to 36 months, showing continuous control of plaque-type psoriasis. Efalizumab has recently been approved in Canada for this indication.
Objective:
To examine the efficacy and safety of efalizumab by presenting the latest data in the treatment of psoriasis.
Methods:
We searched MEDLINE (1966–2005) for randomized, double-blind studies of efalizumab (1 mg/kg for 12 weeks) using the following key words: psoriasis, efalizumab, biologics, and treatment.
Results:
It was found that the proportion of patients who achieved Psoriasis Area and Severity Index (PASI) 75 and PASI 50 ranged from 22 to 39% and 52 to 61%, respectively. PASI 75 improvement was achieved in 44% of patients, who continued to receive efalizumab by week 24. Following 36 months of continuous treatment, a PASI 75 response was achieved by 45% (intent-to-treat [ITT] analysis), 59% (maintenance group analysis), and 73% (as-treated analysis). Its safety profile was similar during the 12-week and 36-month treatment periods.
Conclusions:
Currently, more than 3,500 patients have received efalizumab in clinical trials. Efalizumab may be an important treatment option for dermatologists seeking to provide a well-tolerated and effective treatment modality for patients with moderate to severe chronic plaque psoriasis.
Get full access to this article
View all access options for this article.
References
1.
KruegerJG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol2002;46:1–23.
2.
ElderJTNairRHenslerT. The genetics of psoriasis 2001. Arch Dermatol2001;137:1447–54.
3.
LebwohlM. Psoriasis. Lancet2003;361:1197–204.
4.
ChaudhariURomanoPMulcahyLD. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: A randomised trial. Lancet2001;357:1842–7.
5.
MenterAKosinskiMBresnahanBW. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol2004;3:27–38.
6.
PrinzJC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol2003;17:257–70.
7.
SingriPWestDGordonK. Biologic therapy for psoriasis - the new therapeutic frontier. Arch Dermatol2002;138:657–63.
8.
AustinLMOzawaMKikuchiT. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TCI (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol1999;113:752–9.
9.
GottliebAB. Immunobiologicals for psoriasis: Using targeted immunotherapies as pathogenic probes in psoriasis. In: WeinsteinGDGottliebAB, editors. Therapy of moderate-to-severe-psoriasis. New York: Marcel Dekker; 2003. p. 239–60.
10.
GriffithsCE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol2003;17Suppl 2:1–5.
11.
MenterMAKruegerGFeldmanSWeinsteinGD. Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors. J Am Acad Dermatol2003;49(2 Suppl 1):S39–43.
12.
KreugerGKooJLebwohlM. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol2001;137:280–4.
13.
Tristani-FirouziPKruegerGG. Efficacy and safety of treatment modalities for psoriasis. Cutis1998;61:11–21.
14.
LebwohlMAliS. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol2001;45:649–61.
15.
LebwohlMAliS. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol2001;45:487–98.
16.
National Psoriasis Foundation. Available at: www.psoriasis.org (accessed 2004).
17.
NussbaumRKruegerJG. Treatment of inflammatory dermatoses with novel biologic agents: A primer. Adv Dermatol2002;18:45–89.
18.
LeonardiCL. Efalizumab in the treatment of psoriasis. Dermatol Ther2004;17:393–400.
19.
JullienDPrinzJCLangleyRG. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action. Dermatology2004;208:297–306.
20.
WeinbergJTutroneW. Biologic therapy for psoriasis: The T cell targeted therapies-efalizumab and alefacept. Cutis2003;71:41–5.
21.
Genentech Inc. Raptiva™ (efalizumab) [package insert]. 2003.
22.
MortensenDLWalickePAWangX. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol2005;45:286–98.
23.
GottliebABKruegerJGBrightR. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol2000;42:428–35.
24.
PappKBissonnetteRKruegerJG. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol2001;45:665–74.
25.
GottliebABKruegerJGWittkowskiK. Psoriasis as a model for T cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, and anti-CD1 la antibody. Arch Dermatol2002;138:591–600.
26.
GordonKBPappKAHamiltonTK. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA2003;290:3073–80.
27.
LeonardiCLPappKAGordonKB. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol2005;52:425–33.
28.
LebwohlMTyringSKHamiltonTK. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med2003;349:2004–13.
29.
MenterAGordonKCareyW. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol2005;141:31–8.
30.
GottliebABGordonKHamiltonT. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results. Presented at 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18–22; New Orleans, LA.
31.
LangleyRGShearNHPoulinYGrattonD. Patients with moderate to severe chronic plaque psoriasis improve with efalizumab: initial results of the Clinical Experience Raptiva (CLEAR) trial. Poster presented at the Dermatology Update meeting; 2004 Oct; Vancouver, BC.
32.
CareyWRundleACKwonPLeonardiCL. Taper regimens in the management of patients discontinuing efalizumab therapy. Poster presented at: 11th International Psoriasis Symposium; 2004 June 14–19; Toronto, Canada.
33.
PappKATothD. Safety and efficacy of efalizumab retreatment: final results from an open-label study in psoriasis. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. 2004; Nov 17–21; Florence, Italy.
34.
WeissSCKimballABLiewehrDJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol2002;47:512–8.
35.
ChoiJKooY. Quality of life issues in psoriasis. J Am Acad Dermatol2003;19(2 Suppl 1):S57–61.
36.
GuptaMGuptaA. Depression and suicidal ideation in dermatology patients with acne, alopoecia areata, atopic dermatitis and psoriasis. Br J Dermatol1998;139:846–50.
37.
RappSRFeldmanSRExumML. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol1999;41:401–7.
MenterAPappKA. Safety and tolerability of Efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: Results of an open-label phase IIIb multicentre trial. Presented at 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18–22; New Orleans, LA.
40.
LebwohlM. New developments in the treatment of psoriasis. Arch Dermatol2002;138:686–8.
41.
MenterAKardatzkeDRundleA. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presented at the 10th International Psoriasis Symposium; 2004 June 10–13; Toronto, Canada.
42.
TothDPappK. Managing recurrence of psoriasis following abrupt withdrawal from efalizumab therapy. Poster presented at the 10th International Psoriasis Symposium; 2004 June 10–13; Toronto, Canada.
43.
PappKMillerBLyndeC. Efalizumab (anti-CD11a) retreatment: final results from an open-label study. Presented at the American Academy of Dermatology meeting; 2003 March 21–26; San Francisco, CA.
44.
GordonKPariserDLangleyR. Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: pooled results from randomized phase III trials. Poster presented at the American Academy of Dermatology meeting; 2004 Feb; Washington, DC.
45.
GottliebALizzulPKwonP. Safety and efficacy of efalizumab therapy for elderly patients with moderate to severe chronic plaque psoriasis. Presented at the American Academy of Dermatology meeting; 2005 Feb 18–22; New Orleans, LA.
46.
PappKASobellJTothD. Safety of subcutaneous efalizumab therapy in patients with moderate to severe plaque psoriasis. Presented at Summer Academy 2003 of the American Academy of Dermatology, 2003 July 25–29; Chicago, IL.
